Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer
In a phase 3 trial, atezolizumab plus mFOLFOX6 improved 3-year disease-free survival to 86.3% vs. 76.2% with mFOLFOX6 alone (HR 0.50; 95% CI, 0.35-0.73; P<0.001) in stage III dMMR colon cancer.
Researchers studied a new treatment for stage III colon cancer and found that adding a drug called atezolizumab improved patient outcomes. Patients who received this combination treatment had better c…
CSF ctDNA Status Predicts Survival in Leptomeningeal Metastases: Meta-Analysis
In a meta-analysis of 14 studies (n=963), adverse baseline CSF ctDNA status was linked to worse OS (HR 2.40, 95% CI 1.73-3.33) and PFS (HR 2.45, 95% CI 1.36-4.44) in LMD. Longitudinal CSF ctDNA increa…
Researchers studied a test that checks for cancer DNA in spinal fluid to see if it can predict survival in patients. They found that certain DNA patterns can indicate worse outcomes for patients with …
Guided Breathing VR Reduces Opioid Use Post-PTBD in Cancer Patients by 64%
In a randomized trial, guided breathing VR (VRBG) significantly reduced opioid use post-PTBD compared to conventional VR (VROG), with a mean of 20.25 vs. 56.61 morphine milligram equivalents (P=0.044)…
This study looked at how virtual reality with guided breathing can help manage pain for cancer patients. It found that patients using this method needed less pain medication after a procedure compared…